We have previously reported the establishment of cytotoxic T-cell lines, from pancreatic cancer patients, by continuously stimulating tumor-draining lymph node cells with allogeneic pancreatic tumor cell lines. After the preliminary characterization of their phenotype and tumor specificity, detailed studies performed with one of the cell lines, W.D., show that it recognizes a specific antigen, a large and heavily glycosylated mucin molecule, expressed on pancreatic and breast tumors and tumor cell lines. Although this recognition appears major histocompatibility complex (MHC)-unrestricted, the antigen receptor used by the cytotoxic T cell is the a/fl heterodimer, typically found on MHC-restricted T cells.
The target antigen is atypical, however, in its ability to directly bind and activate the T cells in the absence of self MHC, presumably by abundant and regularly repeated antigenic epitopes. These rmfings are important because they demonstrate a specific T-cell response against a human tumorassociated antigen. In addition to pancreatic and breast tumors, various mucin molecules are known to be produced by other tumors of epithelial cell origin and could be expected to stimulate similar T-cell-mediated immune responses.
Cytotoxic T cells (CTLs) reactive with autologous tumor have been found in the blood (1) , in tumors (2) , and in tumor-draining lymph nodes (3) ofpatients with various types of cancer. We were interested in studying cell-mediated immune responses to tumor-associated antigens in pancreatic adenocarcinoma patients. Because autologous tumor is generally not available from these patients, expansion of pancreatic tumor-reactive T cells, using the prototype mixed lymphocyte-autologous tumor cell culture, was not possible. However, many pancreatic tumor-associated antigens detected on tumor cells in tissues are also expressed on established pancreatic tumor cell lines (4) . This suggested the possibility that allogeneic pancreatic tumor cell lines could be used, in place of autologous tumor, as stimulating antigen in the in vitro expansion of pancreatic-tumor-reactive T cells. Tumor-reactive CTLs that kill both autologous and allogeneic melanomas had been reported (5, 6) . This approach proved justified and we reported (7, 8 ) the establishment of tumor-antigen-specific CTLs using allogeneic pancreatic tumor cell lines as stimulating antigen for lymph-node cells from pancreatic cancer patients. The most interesting characteristic of their function was their apparent tumor-cell specificity but lack of major histocompatibility complex (MHC) restriction. In this report, we examine the cell surface molecules involved in this CTL-tumor cell interaction, at the effector cell level, using a cell line W.D., and the target cell level, to better understand the means by which tumorreactive CTLs may bypass conventional MHC restriction requirements in their recognition of tumor targets. (Philadelphia) . The HPAF tumor cell line has been described (4) . Tumor cell lines were cultured in complete medium supplemented with 10% fetal calf serum. The alloreactive T-cell lines, JBn1 and MH3, and the Epstein-Barr virustransformed B-cell line, JR, were established in our laboratory and described (9) .
MATERIALS AND METHODS
Cytotoxic Assays, Cold Target Inhibition, and Antibody/ Antigen Blocking Studies. Four-hour 51Cr-release assays and calculation of percent specific release were performed as described (10) . For cold target inhibition experiments, unlabeled target cells were mixed with labeled tumor target cells, at various unlabeled to labeled cell ratios, and the mixed cells were added to effector cells for a 4-hr cytotoxic assay.
Antibody-blocking studies were performed by incubating either target cells or effector cells, as indicated, with monoclonal antibody for 45 min at 37TC (6) 16 hr at 370C and harvested using a Skatron cell harvester.
Northern Blot Analysis. Total RNA extraction, gel electrophoresis, and blotting were performed as described (14) . Northern blots were hybridized to a 60-base-pair 32p_ end-labeled oligonucleotide probe synthesized according to the cloned breast mucin gene tandem repeat sequence (15, 16) .
RESULTS
A number of cell lines have been established from lymph nodes of patients with pancreatic adenocarcinoma and their phenotype and function were assayed at various time points in culture. The predominant phenotype of cells, after only 1 month in culture with interleukin 2 and an allogeneic pancreatic tumor cell line as antigen, is in all cases CD3' CD8' CD4-Leu7-Leull-Leu19-, and the predominant activity is a pancreatic-tumor-directed MHC-unrestricted cytotoxicity (7, 8) . Extensive (Table 1 ). The specificity of lysis remained restricted to these same tumor targets at effector to target (E/T) ratios as high as 40:1 (data not shown). Cold target inhibition experiments were performed to examine whether the epitope recognized on the breast tumor targets and the ovarian tumor target OVCA-420 was indeed the same as that recognized on the pancreatic tumor targets. At a target to inhibitor ratio of 1:5, all breast tumor cell lines tested inhibited W.D.-mediated lysis of the pancreatic tumor target PANC-89 by at least 50%o, similar in magnitude to the effect of adding PANC-89 itself or the pancreatic tumor cell line CAPAN-2 as cold targets. At a target to inhibitor ratio of 1:10, the ovarian tumor cell line lysed by W.D. (OVCA-420) inhibited lysis of PANC-89 by 27%, whereas tumor cell lines which were not lysed by W.D. cells (OVCA-432, K562) inhibited lysis of PANC-89 by only 6% (Fig. 1) .
The fact that W.D. cells kill in an antigen-specific, yet apparently non-MHC-restricted manner raised questions regarding the involvement of the TCR in allogeneic tumor recognition and lysis. In addition, the role of monomorphic MHC determinants on the target cell and of T-cell accessory molecule, CD8, which is expressed on these CTLs, needed to be examined. Monoclonal antibodies directed against the TCR-associated CD3 complex (OKT3 Ab), the CD8 molecule (OKT8 Ab), and monomorphic MHC class I determinants (W6/32 Ab) were tested for their ability to inhibit lysis of a pancreatic tumor target CAPAN-2 by W.D. cells. Antibodies to molecules not expressed on the CTL, CD4 (OKT4 Ab) and DU-PAN-1, were used as controls. As is shown in Table 2 , preincubation of W.D. cells with OKT3 antibody greatly inhibited their function (up to 72%). Antibody OKT8 had a less dramatic but significant effect (35% inhibition), which equaled the effect of preincubation of the target cell with W6/32 antibody ( Table 2 ). In contrast, the effect of OKT4 antibody (18% inhibition) was only slightly higher than that of a control antibody, DU-PAN-1 (9% inhibition).
The inhibitory effect of OKT3 antibody suggested that the lytic activity exhibited by W.D. cells involves the CD3-associated antigen-specific TCR. We were, therefore, interested in identifying the TCR components expressed by these CTLs. After chemical cross-linking of 251I-labeled W.D. cell surface proteins and immunoprecipitation with Leu4 antibody, the CD3-associated polypeptides were identified by SDS/PAGE analysis as TCR a and 1 chains (Fig. 2, lane 2) . The same two chains were brought down when BF1 was used as the precipitating antibody (Fig. 2, lane 3 mucins, being very large, highly glycosylated molecules with multiple antigenic epitopes for monoclonal antibody binding (15) , might be capable of directly stimulating W.D. cells, which would help explain the MHC-unrestricted nature of their recognition. Pancreatic tumor mucins were purified as described (19) and compared to whole pancreatic tumor cells in their ability to stimulate proliferation of W.D. cells and specifically block their lysis. Several anti-tumor mucin antibodies, selected for their reactivity with the mucin polypeptide core rather than the carbohydrate determinants, were also tested for their ability to block W.D.-mediated lysis of tumor targets.
As shown in Table 3 , purified pancreatic tumor mucins were found to directly stimulate W.D. cell proliferation in the absence of antigen-presenting cells but had no stimulatory effect on an alloreactive T-cell line, JBnl, established from a liver transplant patient and specific for the donor HLA antigens. The mucin-induced proliferation was comparable to that stimulated with intact tumor cells.
In addition to having a proliferative effect, purified pancreatic tumor mucins could also inhibit W.D.-mediated lysis ofthe pancreatic tumor target PANC-89 by about 50% at each E/T ratio tested but had no such effect on the lytic activity of another control alloreactive CTL, MH3, against its specific target JR (Table 4) . Blocking experiments are difficult to perform with an antigen that, at the same time, can directly stimulate the CTLs. At lower E/T ratios the observed effect is thus a net result of a concurrent stimulatory and blocking Results shown are from a single experiment but are representative of results obtained in three experiments. Pancreatic tumor mucin (PTM) was used at 1900 DU-PAN-2 units/ml. SM3 antibody was used at 20 jig/ml. activity, and the expected increase in blocking with the decrease in effector cell numbers is seldom seen.
Murine anti-mucin monoclonal antibodies were obtained from various sources and each was tested for its ability to inhibit W.D.-mediated lysis. One antibody, SM3, reported to recognize an epitope present within the first 7 amino acids of the 20 amino acid core peptide of breast tumor mucin molecules (20) , effectively inhibited W.D.-mediated lysis of both pancreatic and breast tumor cell lines (Table 4 ). Other monoclonal antibodies tested, including one reactive with a pancreatic mucin (DU-PAN-2) (19) and one directed to a different epitope present within the last 10 amino acids of the breast tumor mucin core peptide (BC3) (21) , had no such inhibitory effect (data not shown).
Having express an RNA transcript hybridizing with an oligonucleotide probe comprising a 60-base-pair tandem repeat sequence of the cloned breast mucin gene (15, 16) (Fig. 3) . Although blocking effects of W6/32 antibody indicate that MHC class I molecules on the target cell participate to some degree in the W.D.-tumor cell interaction, comparable blocking effects with anti-CD8 antibody suggest that this participation may involve accessory interactions of CD8 molecules with monomorphic determinants on class I MHC molecules. With regard to the specific T-cell interaction with its target antigen, however, it appears that TCR recognition of polymorphic self MHC determinants is not required for multivalent antigen recognition, as is the case for specific recognition of univalent antigens.
MHC-restricted recognition has often been suggested as a mechanism by which CTLs are "directed" to target cell surfaces. It is interesting to speculate that tumor cell production of high levels of circulating mucin, such as is known to occur in pancreatic and breast cancer (21, 26) , may help tumor cells to escape immune destruction by engaging tumorspecific T-cell clones in the periphery with the soluble antigen.
Our observation that a patient can mount an immune response against tumor-associated mucins brings up a number of important questions. Is the tumor-associated mucin seen by these CTLs different from mucin produced by normal pancreatic or breast ductal epithelial cells, and, if it isn't, why would the immune system view it as foreign? There are a number of monoclonal antibodies, including the SM3 antibody, that are more strongly reactive with tumors than with normal tissue, suggesting the appearance of new tumorassociated epitopes (27) . On the other hand, it may be possible that mucins are normally not accessible to the immune system as they are secreted directly into ducts. Malignant transformation of the mucin-producing cells releases high levels of these molecules into the circulation, which then act as endogenous antigens.
In either case it might be possible to manipulate this immune response or reduce circulating tumor mucins to effect the elimination of the tumor or of the metastases after the primary tumor is removed. This however calls for better insight into post-operative treatments that are now based on aggressive chemotherapy and tend to completely destroy an already established immune response.
